75 WEST CENTER ST, PROVO, UT
Executive VP Justin Keisel Begins Medical Leave of Absence
Reports Second Quarter Results
Stockholders Approve Amended 2024 Omnibus Incentive Plan
Executive Departure - Steven K. Hatchett Resigns as Chief Product Officer
Reports First Quarter Results
Annual Report to Security Holders
Nu Skin Enterprises Enters $175 Million Credit Agreement
Appoints Chelsea Lantz as Interim Chief Financial Officer
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
RW
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Specialized Disclosure Report
S-8 POS